Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Discloses Dako Earnings

NEW YORK (GenomeWeb News) – Through eight months ending May 31, 2012, Dako posted $242 million in revenues, Agilent Technologies disclosed in a regulatory filing after the close of the market on Wednesday, which also disclosed Dako's earnings for full-year 2011 and for the six months ended March 31.

Agilent completed its $2.2 billion purchase of the Danish cancer diagnostics company in June.

In a document filed with the US Securities and Exchange Commission on Wednesday, Agilent said that Dako had a net loss of $61 million on a GAAP basis for the eight months ended May 31. R&D spending during the period totaled $37 million and SG&A costs were $100 million.

During the six months ended March 31, Dako posted revenues of $183 million and a net loss of $23 million. It spent $24 million on R&D and $76 million on SG&A. In full-year 2011, the firm had a loss of $43 million on revenues of $361 million. R&D spending was $51 million for FY 2011, while SG&A spending was $155 million.

The Scan

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.

Study Looks at Parent Uncertainties After Children's Severe Combined Immunodeficiency Diagnoses

A qualitative study in EJHG looks at personal, practical, scientific, and existential uncertainties in parents as their children go through SCID diagnoses, treatment, and post-treatment stages.

Antimicrobial Resistance Study Highlights Key Protein Domains

By screening diverse versions of an outer membrane porin protein in Vibrio cholerae, researchers in PLOS Genetics flagged protein domain regions influencing antimicrobial resistance.

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.